- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742856
A Multi-omics Study of Epithelial Ovarian Cancer
November 13, 2018 updated by: Lei Li
A Multi-omics Study on the Invasiveness of Epithelial Ovarian Cancer
This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes.
The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics.
A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Lei Li
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients confirmed primary epithelial ovarian cancer will be included for analysis.
Description
Inclusion Criteria:
- Confirmed primary epithelial ovarian cancer
- Signed an approved informed consents
- Feasible for biopsy
Exclusion Criteria:
- Not meeting all of the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequencies of somatic driving mutations
Time Frame: Two years
|
The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Five years
|
Progression-free survival between patients with differential expressed multi-omics will be compared.
|
Five years
|
Frequencies of alteration of RNA expression
Time Frame: Two years
|
The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes.
|
Two years
|
Frequencies of alteration of protein expression and signal pathway
Time Frame: Two years
|
The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes.
|
Two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2018
Primary Completion (Anticipated)
November 23, 2020
Study Completion (Anticipated)
November 23, 2020
Study Registration Dates
First Submitted
November 9, 2018
First Submitted That Met QC Criteria
November 13, 2018
First Posted (Actual)
November 15, 2018
Study Record Updates
Last Update Posted (Actual)
November 15, 2018
Last Update Submitted That Met QC Criteria
November 13, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplastic Processes
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Carcinogenesis
Other Study ID Numbers
- EOC-OMICS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epithelial Ovarian Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedFallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity CancerCanada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Epithelial Cancer | Recurrent Ovarian Germ Cell Tumor | Stage IIIA Ovarian Germ Cell Tumor | Stage IIIB Ovarian Germ Cell... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditionsUnited States
-
Life Research Technologies GmbHUnknownOvarian Epithelial CancerAustria, Hungary
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIIA Primary... and other conditionsUnited States
Clinical Trials on A multi-omics analysis
-
Lei LiUnknownEndometriosis | Adenomyosis | Genomics | Metabolomics | Ectopic Endometrium | Eutopic Endometrium | TranscriptomicsChina
-
Lei LiUnknownCervical Adenocarcinoma | Human Papillomavirus | Metabolome | Prognosis | Whole Exome Sequencing | Tumorigenesis | Transcriptome | Genome-wide Association StudyChina
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
Capital Medical UniversityRecruitingSevere Community-acquired PneumoniaChina
-
GeneCast Biotechnology Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingGastric CancerChina
-
Zhejiang Cancer HospitalSun Yat-sen University; Shanghai Zhongshan Hospital; Fujian Cancer Hospital; RenJi... and other collaboratorsRecruitingMalignant Tumors of Digestive TractChina
-
University Hospital TuebingenRecruiting
-
Fudan UniversityUnknownColorectal Cancer Metastatic
-
Peking University Third HospitalPeking UniversityRecruitingHeart Failure | Percutaneous Coronary Intervention | Cardiometabolic Syndrome | Structural Heart AbnormalityChina
-
CENTOGENE GmbH RostockActive, not recruiting